Experts on their own experiences: the rise of patient-reported outcomes in oncology drug trials

Leuk Lymphoma. 2019 Nov;60(11):2604-2605. doi: 10.1080/10428194.2019.1632446. Epub 2019 Jul 4.

Author

Thomas W LeBlanc^{1

2}

Affiliations

¹ Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
² Duke Cancer Institute, Durham, NC, USA.

PMID: 31271323
DOI: 10.1080/10428194.2019.1632446

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Hodgkin Disease*
Humans
Medical Oncology
Patient Reported Outcome Measures

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab